Literature DB >> 33870023

Platelet Src family kinases: A tale of reversible phosphorylation.

Yotis A Senis1, Zoltan Nagy2, Jun Mori3, Sophia Lane4, Patrick Lane4.   

Abstract

Sarcoma (Src) family kinases (SFKs) have occupied a central place in platelet research for over 40 years. Discovered by virologists and oncologists as the proto proto-oncogene, Src tyrosine kinase spurred a phenomenal burst of research on reversible tyrosine phosphorylation and signal transduction. For a time, platelets were adopted as the model of choice for studying the biological functions of Src, owing to their ease of isolation, high Src expression, and lack of a nucleus, only to be abandoned due to challenges of culturing and manipulating using common molecular biology-based techniques. For platelet biologists, SFKs have remained an important area of investigation, initiating and amplifying signals from all major adhesion, activation, and inhibitory receptors, including the integrin αIIbβ3, the collagen receptor complex glycoprotein VI-Fc receptor γ-chain, the G protein-coupled ADP receptor P2Y12 and the inhibitory receptors platelet endothelial cell adhesion molecule-1 and G6b-B. The vital roles of SFKs in platelets is highlighted by the severe phenotypes of null and gain-of-function mutations in SFKs in mice and humans, and effects of pharmacologic inhibitors on platelet activation, thrombosis, and hemostasis. The recent description of critical regulators of SFKs in platelets, namely, C-terminal Src kinase (Csk), Csk homologous kinase (Chk), the receptor-type protein-tyrosine phosphatase receptor type J (PTPRJ) helps explain some of the bleeding side effects of tyrosine kinase inhibitors and are novel therapeutic targets for regulating the thrombotic and hemostatic capacity of platelets. Recent findings from Chk, Csk, and PTPRJ knockout mouse models highlighted that SFKs are able to autoinhibit by phosphorylating their C-terminal tyrosine residues, providing fundamental insights into SFK autoregulation.
© 2021 Research and Practice in Thrombosis and Haemostasis published by Wiley Periodicals LLC on behalf of International Society on Thrombosis and Haemostasis.

Entities:  

Keywords:  Src; kinase; phosphatatase; platelets; tyrosine phosphorylation

Year:  2021        PMID: 33870023      PMCID: PMC8035799          DOI: 10.1002/rth2.12495

Source DB:  PubMed          Journal:  Res Pract Thromb Haemost        ISSN: 2475-0379


Sarcoma (Src) family kinases (SFKs) are essential for initiating and amplifying platelet activation. Reversible phosphorylation is a primary mode of regulation of SFK activity. The tyrosine kinases C‐terminal Src kinase (Csk) and Csk homologous kinase and phosphatase protein‐tyrosine phosphatase receptor type J are critical regulators of SFKs. Autophosphorylation provides an additional level of SFK regulation.

AUTHOR CONTRIBUTIONS

YAS developed theme, prepared images, and wrote and revised the manuscript. ZN prepared images and revised the manuscript. JM developed theme and prepared images. SL developed theme, illustration, and design. PL developed theme, illustration, and design.

RELATIONSHIP DISCLOSURE

The authors report no conflicts of interest to disclose.
  56 in total

1.  Conversion of phosphorylase b to phosphorylase a in muscle extracts.

Authors:  E H FISCHER; E G KREBS
Journal:  J Biol Chem       Date:  1955-09       Impact factor: 5.157

2.  Uninfected vertebrate cells contain a protein that is closely related to the product of the avian sarcoma virus transforming gene (src).

Authors:  H Oppermann; A D Levinson; H E Varmus; L Levintow; J M Bishop
Journal:  Proc Natl Acad Sci U S A       Date:  1979-04       Impact factor: 11.205

3.  Blood platelets express high levels of the pp60c-src-specific tyrosine kinase activity.

Authors:  A Golden; S P Nemeth; J S Brugge
Journal:  Proc Natl Acad Sci U S A       Date:  1986-02       Impact factor: 11.205

4.  Maintenance of murine platelet homeostasis by the kinase Csk and phosphatase CD148.

Authors:  Jun Mori; Zoltan Nagy; Giada Di Nunzio; Christopher W Smith; Mitchell J Geer; Rashid Al Ghaithi; Johanna P van Geffen; Silke Heising; Luke Boothman; Bibian M E Tullemans; Joao N Correia; Louise Tee; Marijke J E Kuijpers; Paul Harrison; Johan W M Heemskerk; Gavin E Jarvis; Alexander Tarakhovsky; Arthur Weiss; Alexandra Mazharian; Yotis A Senis
Journal:  Blood       Date:  2018-01-04       Impact factor: 22.113

5.  Low level of cellular protein phosphorylation by nontransforming overproduced p60c-src.

Authors:  H Iba; F R Cross; E A Garber; H Hanafusa
Journal:  Mol Cell Biol       Date:  1985-05       Impact factor: 4.272

6.  An activity phosphorylating tyrosine in polyoma T antigen immunoprecipitates.

Authors:  W Eckhart; M A Hutchinson; T Hunter
Journal:  Cell       Date:  1979-12       Impact factor: 41.582

7.  Dominant role of the protein-tyrosine phosphatase CD148 in regulating platelet activation relative to protein-tyrosine phosphatase-1B.

Authors:  Jun Mori; Ying-Jie Wang; Stuart Ellison; Silke Heising; Benjamin G Neel; Michel L Tremblay; Steve P Watson; Yotis A Senis
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-10-11       Impact factor: 8.311

8.  Expression of DEP-1, a receptor-like protein-tyrosine-phosphatase, is enhanced with increasing cell density.

Authors:  A Ostman; Q Yang; N K Tonks
Journal:  Proc Natl Acad Sci U S A       Date:  1994-10-11       Impact factor: 11.205

9.  Potential positive and negative autoregulation of p60c-src by intermolecular autophosphorylation.

Authors:  J A Cooper; A MacAuley
Journal:  Proc Natl Acad Sci U S A       Date:  1988-06       Impact factor: 11.205

10.  The tyrosine phosphatase CD148 is an essential positive regulator of platelet activation and thrombosis.

Authors:  Yotis A Senis; Michael G Tomlinson; Stuart Ellison; Alexandra Mazharian; Jenson Lim; Yan Zhao; Kristin N Kornerup; Jocelyn M Auger; Steve G Thomas; Tarvinder Dhanjal; Neena Kalia; Jing W Zhu; Arthur Weiss; Steve P Watson
Journal:  Blood       Date:  2009-02-25       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.